All Stories

  1. Connecting the mammalian immune system with bacterial chemical signaling
  2. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors
  3. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors
  4. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity
  5. Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest
  6. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors
  7. MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
  8. Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting
  9. Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes
  10. Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
  11. Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis
  12. Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review
  13. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines
  14. Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK–NF-κB signaling mediated inflammation
  15. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations
  16. Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21
  17. The versatile nature of miR-9/9* in human cance
  18. Major Vault Protein, a Candidate Gene in 16p11.2 Microdeletion Syndrome, Is Required for the Homeostatic Regulation of Visual Cortical Plasticity
  19. Prognostic Circulating MicroRNA Biomarkers in Early-Stage Non-Small Cell Lung Cancer: A Role for miR-150
  20. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors
  21. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial
  22. Loss of SLCO1B3 drives taxane resistance in prostate cancer
  23. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation
  24. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment
  25. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Caba...
  26. MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells
  27. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice
  28. Inducible Major Vault Protein Plays a Pivotal Role in Double-Stranded RNA– or Virus-Induced Proinflammatory Response
  29. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway
  30. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes
  31. Lysosomal Sequestration Determines Intracellular Imatinib Levels
  32. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
  33. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
  34. MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response
  35. Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area
  36. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
  37. Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
  38. MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α
  39. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors
  40. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity
  41. Incident cancer risk after the start of aspirin use: Results from a Dutch population-based cohort study of low dose aspirin users
  42. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
  43. Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
  44. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours
  45. A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform
  46. Gene Expression Profiling of Histiocytic Sarcomas in a Canine Model: The Predisposed Flatcoated Retriever Dog
  47. The issue of non-specific binding of cabazitaxel
  48. Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
  49. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen
  50. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
  51. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs
  52. Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials
  53. Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer
  54. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin
  55. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
  56. A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
  57. Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
  58. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding
  59. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
  60. Stressed tumor cell, chemosensitized cancer
  61. Recruitment of the Major Vault Protein by InlK: A Listeria monocytogenes Strategy to Avoid Autophagy
  62. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study
  63. microRNAs in stage I epithelial ovarian cancer
  64. Drug transporters of platinum-based anticancer agents and their clinical significance
  65. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
  66. Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
  67. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
  68. Effects of methimazole on the elimination of irinotecan
  69. MicroRNAs in ovarian cancer biology and therapy resistance
  70. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study
  71. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry
  72. MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation
  73. A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan
  74. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)
  75. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry
  76. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response
  77. The Applicability of mTOR Inhibition in Solid Tumors
  78. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1
  79. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
  80. The spliceosome as target for anticancer treatment
  81. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
  82. In Reply
  83. Editorial: The Long and Winding Road to Better Cancer Cell-Specific Therapies
  84. A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy
  85. Dose Selection in Phase I Studies: Why We Should Always Go for the Top
  86. Renal Function as a Predictor of Irinotecan-induced Neutropenia
  87. Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
  88. Pitfalls of the application of microdialysis in clinical oncology: Controversial findings with docetaxel
  89. Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells
  90. The role of microRNAs in cancer: No small matter
  91. Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment
  92. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
  93. Practical Aspects of Managing Gastrointestinal Stromal Tumors
  94. The Relevance of Microdialysis for Clinical Oncology
  95. Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope
  96. Major Vault Protein, in Concert with Constitutively Photomorphogenic 1, Negatively Regulates c-Jun–Mediated Activator Protein 1 Transcription in Mammalian Cells
  97. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump
  98. Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression
  99. Resistance to Platinum-Containing Chemotherapy in Testicular Germ Cell Tumors Is Associated with Downregulation of the Protein Kinase SRPK1
  100. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine
  101. The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling
  102. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP
  103. Vaults: a ribonucleoprotein particle involved in drug resistance?
  104. The vault complex
  105. Unimpaired dendritic cell functions in MVP/LRP knockout mice
  106. The genomic sequence of the murine major vault protein and its promoter
  107. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
  108. Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein
  109. Structural Domains of Vault Proteins: A Role for the Coiled Coil Domain in Vault Assembly
  110. Multiple Human Vault RNAs
  111. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia
  112. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)
  113. MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7
  114. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer
  115. Visualization of the Peroxisomal Compartment in Living Mammalian Cells: Dynamic Behavior and Association with Microtubules
  116. Signals, Receptors, and Cytosolic Factors Involved in Peroxisomal Protein Import
  117. Identification of 2-enoyl coenzyme A hydratase and NADP+-dependent 3-hydroxyacyl-CoA dehydrogenase activity in glycosomes of procyclic Trypanosoma brucei
  118. Isolation and Characterization of Pas2p, a Peroxisomal Membrane Protein Essential for Peroxisome Biogenesis in the Methylotrophic YeastPichia pastoris
  119. Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal disorders
  120. Molecular analysis of glyceraldehyde-3-phosphate dehydrogenase in Trypanoplasma borelli: An evolutionary scenario of subcellular compartmentation in Kinetoplastida
  121. Topology of catalase assembly in human skin fibroblasts
  122. The electrochemical proton gradient in the bloodstream form of Trypanosoma brucei is dependent on the temperature
  123. Production and characterisation of monoclonal antibodies against native and disassembled human catalase
  124. Pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei is mediated by a facilitated diffusion carrier
  125. Phenotypic heterogeneity in cultured skin fibroblasts from patients with disorders of peroxisome biogenesis belonging to the same complementation group
  126. Prenatal Diagnosis of Zellweger Syndrome by Direct Visualization of Peroxisomes in Chorionic Villus Fibroblasts by Immunofluorescence Microscopy
  127. Kinetics of the assembly of peroxisomes after fusion of complementary cell lines from patients with the cerebro-hepato-renal (Zellweger) syndrome and related disorders